{"id":674491,"date":"2026-03-26T11:50:57","date_gmt":"2026-03-26T10:50:57","guid":{"rendered":"https:\/\/www.interactiegroep.nl\/?page_id=674491"},"modified":"2026-06-10T09:29:28","modified_gmt":"2026-06-10T07:29:28","slug":"celltrion-090626","status":"publish","type":"page","link":"https:\/\/www.interactiegroep.nl\/en\/celltrion-090626\/","title":{"rendered":"Optimale infliximab toepassing anno 2026 bij IBD"},"content":{"rendered":"<p><img decoding=\"async\" data-src=\"\/wp-content\/uploads\/2026\/04\/Banner.png\" alt=\"\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" style=\"--smush-placeholder-width: 1600px; --smush-placeholder-aspect-ratio: 1600\/400;\" data-srcset=\"https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2026\/04\/Banner.png 1600w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2026\/04\/Banner-300x75.png 300w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2026\/04\/Banner-1024x256.png 1024w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2026\/04\/Banner-768x192.png 768w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2026\/04\/Banner-1536x384.png 1536w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2026\/04\/Banner-18x5.png 18w, https:\/\/www.interactiegroep.nl\/wp-content\/uploads\/2026\/04\/Banner-600x150.png 600w\" data-sizes=\"auto\" data-original-sizes=\"(max-width: 1600px) 100vw, 1600px\"><br \/>\n<iframe data-src=\"https:\/\/vimeo.com\/1177286231?share=copy&#038;fl=sv&#038;fe=ci\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" data-load-mode=\"1\"><\/iframe><\/p>\n<table>\n<tbody>\n<tr>\n<td>Leerdoel<\/td>\n<td>Aan de hand van meerdere stellingen zullen verschillende aspecten van IBD behandeling aan bod komen: Wanneer moet je starten met biologische middelen? Hoe verhoudt de farmacokinetiek zich ten opzichte van de farmacodynamiek? Wanneer kies je monotherapie en wanneer combinatie therapie?<\/td>\n<\/tr>\n<tr>\n<td>Competenties<\/td>\n<td>100% wetenschappelijk<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr>\n<div>NL&#8211;26-00007 &#8211; April 2026<\/div>\n<p><!--more--><br \/>\n<!-- {\"type\":\"layout\",\"children\":[{\"type\":\"section\",\"props\":{\"image_position\":\"center-center\",\"style\":\"default\",\"title_breakpoint\":\"xl\",\"title_position\":\"top-left\",\"title_rotation\":\"left\",\"vertical_align\":\"middle\",\"width\":\"default\"},\"children\":[{\"type\":\"row\",\"children\":[{\"type\":\"column\",\"props\":{\"image_position\":\"center-center\",\"position_sticky_breakpoint\":\"m\"},\"children\":[{\"type\":\"image\",\"props\":{\"image\":\"wp-content\\\/uploads\\\/2026\\\/04\\\/Banner.png\",\"image_border\":\"rounded\",\"image_svg_color\":\"emphasis\",\"margin\":\"default\"}},{\"type\":\"video\",\"props\":{\"margin\":\"default\",\"video\":\"https:\\\/\\\/vimeo.com\\\/1177286231?share=copy&fl=sv&fe=ci\",\"video_controls\":true,\"video_width\":1920}},{\"type\":\"text\",\"props\":{\"block_align\":\"center\",\"column_breakpoint\":\"m\",\"content\":\"\n\n<p>Stellingen die besproken gaan worden:<\\\/p>\\n\n\n<ol>\\n\n\n<li>Infliximab is eerste keus therapie bij IBD<\\\/li>\\n\n\n<li>Infliximab SC heeft voorkeur boven infliximab IV<\\\/li>\\n\n\n<li>Infliximab SC moet getitreerd tot dezelfde referentie spiegels als infliximab IV<\\\/li>\\n\n\n<li>Met infliximab SC is combotherapie niet aangewezen<\\\/li>\\n<\\\/ol>\",\"margin\":\"medium\",\"maxwidth\":\"2xlarge\",\"status\":\"disabled\"}},{\"type\":\"grid\",\"props\":{\"block_align\":\"center\",\"content_column_breakpoint\":\"m\",\"filter_align\":\"left\",\"filter_all\":true,\"filter_grid_breakpoint\":\"m\",\"filter_grid_width\":\"auto\",\"filter_position\":\"top\",\"filter_style\":\"tab\",\"grid_default\":\"1\",\"grid_medium\":\"\",\"icon_width\":80,\"image_align\":\"bottom\",\"image_grid_breakpoint\":\"m\",\"image_grid_width\":\"1-2\",\"image_svg_color\":\"emphasis\",\"item_animation\":true,\"lightbox_bg_close\":true,\"link_style\":\"default\",\"link_text\":\"Read more\",\"margin\":\"xlarge\",\"margin_remove_top\":true,\"maxwidth\":\"2xlarge\",\"meta_align\":\"below-title\",\"meta_element\":\"div\",\"meta_margin\":\"small\",\"meta_style\":\"h5\",\"panel_image_no_padding\":true,\"panel_padding\":\"default\",\"panel_style\":\"card-default\",\"show_content\":true,\"show_hover_image\":true,\"show_hover_video\":true,\"show_image\":true,\"show_link\":true,\"show_meta\":true,\"show_title\":true,\"show_video\":true,\"status\":\"disabled\",\"title_align\":\"top\",\"title_color\":\"primary\",\"title_element\":\"h3\",\"title_grid_breakpoint\":\"m\",\"title_grid_width\":\"1-2\",\"title_hover_style\":\"reset\"},\"children\":[{\"type\":\"grid_item\",\"props\":{\"content\":\"\n\n<p>Dinsdag 9 juni 2026<br \\\/>19u30 - 20u30<\\\/p>\\n\n\n<p>[gravityform id=\\\"71\\\" title=\\\"false\\\"]<\\\/p>\",\"image\":\"\",\"meta\":\"Inzichten van een MDL-arts en ziekenhuisapotheker\",\"title\":\"Scientific webinar: Optimale infliximab toepassing anno 2026 bij IBD\"}}]},{\"type\":\"table\",\"props\":{\"block_align\":\"center\",\"image_svg_color\":\"emphasis\",\"link_style\":\"default\",\"link_text\":\"Read more\",\"margin\":\"medium\",\"maxwidth\":\"2xlarge\",\"meta_style\":\"text-meta\",\"show_content\":true,\"show_image\":true,\"show_link\":true,\"show_meta\":true,\"show_title\":true,\"table_order\":\"1\",\"table_responsive\":\"overflow\",\"table_size\":\"small\",\"table_style\":\"divider\",\"table_width_meta\":\"shrink\",\"table_width_title\":\"shrink\",\"title_style\":\"h5\"},\"children\":[{\"type\":\"table_item\",\"props\":{\"content\":\"Aan de hand van meerdere stellingen zullen verschillende aspecten van IBD behandeling aan bod komen: Wanneer moet je starten met biologische middelen? Hoe verhoudt de farmacokinetiek zich ten opzichte van de farmacodynamiek? Wanneer kies je monotherapie en wanneer combinatie therapie?\",\"title\":\"Leerdoel\"}},{\"type\":\"table_item\",\"props\":{\"content\":\"100% wetenschappelijk\",\"title\":\"Competenties\"}}]},{\"type\":\"divider\",\"props\":{\"divider_element\":\"hr\"}},{\"type\":\"text\",\"props\":{\"column_breakpoint\":\"m\",\"content\":\"NL--26-00007 - April 2026\",\"margin\":\"default\",\"text_style\":\"meta\"}}]}]}]}],\"version\":\"4.5.31\"} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Leerdoel Aan de hand van meerdere stellingen zullen verschillende aspecten van IBD behandeling aan bod komen: Wanneer moet je starten met biologische middelen? Hoe verhoudt de farmacokinetiek zich ten opzichte van de farmacodynamiek? Wanneer kies je monotherapie en wanneer combinatie therapie? Competenties 100% wetenschappelijk NL&#8211;26-00007 &#8211; April 2026<\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-674491","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.interactiegroep.nl\/en\/wp-json\/wp\/v2\/pages\/674491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interactiegroep.nl\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.interactiegroep.nl\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.interactiegroep.nl\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interactiegroep.nl\/en\/wp-json\/wp\/v2\/comments?post=674491"}],"version-history":[{"count":0,"href":"https:\/\/www.interactiegroep.nl\/en\/wp-json\/wp\/v2\/pages\/674491\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.interactiegroep.nl\/en\/wp-json\/wp\/v2\/media?parent=674491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}